May 05, 2020
Jupiter Orphan Therapeutics, Inc. Strengthens its Advisory Positions
Dec 18, 2019
REGENXBIO Announces Interim Data from Phase I/II Trial of RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II)
Dec 04, 2019
Hunter Syndrome Treatment Market Size, Share & Trend Analysis By Treatment, By Region And Segment Forecasts, 2019 - 2026
Oct 23, 2019
Allievex Completes Series A Financing Led by Pappas Capital and Novo Holdings
Jul 03, 2019
Mucopolysaccharidosis (MPS) Treatment Market: Global Industry Analysis 2014-2018 and Opportunity Assessment 2019-2029
Jun 04, 2019
BioMarin Announces Approval of Vimizim® (elosulfase alfa) in China for Treatment of Morquio A Syndrome
Sep 05, 2018
Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II (Hunter Syndrome)
Aug 17, 2018
2018 Mucopolysaccharidosis Disorders Drug Development Pipeline Review
Aug 10, 2018
First Patient Dosed in Phase 1/2 Study Evaluating SOBI003 for Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)
Aug 02, 2018
ArmaGen Receives U.S. Orphan Drug Designation for AGT-184
Jul 27, 2018
Sangamo To Host Educational Webcast With Hunter Syndrome (MPS II) Expert, Joseph Muenzer, M.D., Ph.D.
Jul 10, 2018
ArmaGen's AGT-181 52-Week Phase 1/2 Proof-of-Concept Study Results Published in Orphanet Journal of Rare Diseases
Jun 12, 2018
REGENXBIO Receives FDA Fast Track Designation for RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I
Jun 05, 2018
Mucopolysaccharidosis III (Sanfilippo syndrome) Pipeline Analysis 2018: 12 Drugs Currently in Different Phases of Development
Jun 04, 2018
Sangamo Announces U.K. Authorization Of Clinical Trials Evaluating Zinc Finger Nuclease In Vivo Genome Editing Treatments SB-318 For MPS I And SB-913 For MPS II
Jun 04, 2018
Mucopolysaccharidosis I (Hurler Syndrome) Pipeline Analysis, H1 2018 with Profiles of ArmaGen, Angiochem and JCR Pharmaceuticals
May 15, 2018
REGENXBIO Joins the Mucopolysaccharidosis Community to Advance Research and Innovation
May 15, 2018
Shire Recognizes MPS Awareness Day 2018 with Digital Campaign and Global Events Focused on Increasing Diseases Awareness
May 02, 2018
REGENXBIO Receives FDA Fast Track Designation for RGX-121 Gene Therapy for the Treatment of Mucopolysaccharidosis Type II
Apr 09, 2018
Perlara announces partnership with Multiple Sulfatase Deficiency Action Foundation